Details of the Drug

General Information of Drug (ID: DM0BT41)

Drug Name

NYX-458

Synonyms

Nevadistinel; YYL9TO6TW2; NEVADISTINEL [USAN]; SCHEMBL19850602; NYX-458; NYX-3054; HY-156626; CS-0886462; (4S)-2-[(4-Methoxyphenyl)methyl]-2,7-diazaspiro[3.5]nonane-1,6-dione; 2,7-Diazaspiro[3.5]nonane-1,6-dione, 2-[(4-methoxyphenyl)methyl]-, (4S)-; 2181816-92-0

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Phase 2	[1]

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C15H18N2O3
Canonical SMILES: COC1=CC=C(C=C1)CN2CC3(C2=O)CCNC(=O)C3
InChI: InChI=1S/C15H18N2O3/c1-20-12-4-2-11(3-5-12)9-17-10-15(14(17)19)6-7-16-13(18)8-15/h2-5H,6-10H2,1H3,(H,16,18)/t15-/m0/s1
InChIKey: HMFZRGIXXDQHFG-HNNXBMFYSA-N

Cross-matching ID

PubChem CID: 134241459
TTD ID: DB8V4Z

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
N-methyl-D-aspartate receptor (NMDAR)	TT9IK2Z	NOUNIPROTAC	Modulator	[2]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04148391) A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia. U.S.National Institutes of Health.
2	NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model. Mov Disord. 2020 Apr;35(4):640-649.